✦ LIBER ✦

Secondary mutations of c-KIT contribute to acquired resistance to imatinib and decrease efficacy of sunitinib in Chinese patients with gastrointestinal stromal tumors

✍ Scribed by Gao, Jing; Tian, Ye; Li, Jian; Sun, Naiping; Yuan, Jiajia; Shen, Lin

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

C-KIT mutations were closely associated

✍ Jing Gao, Yunzhi Dang, Naiping Sun, Jian Li, Lin Shen 📂 Article 📅 2012 🏛 Springer US 🌐 English ⚖ 296 KB

Efficacy and safety of motesanib, an ora

✍ Robert S. Benjamin; Patrick Schöffski; Jörg Thomas Hartmann; Allan Van Oosterom; 📂 Article 📅 2010 🏛 Springer 🌐 English ⚖ 438 KB

212 POSTER A phase II study of the KIT i

✍ A.J. Wagner; S. Yazji; J.A. Morgan; E. Choy; S. George; M. Hohos; M. O'Mara; G.D 📂 Article 📅 2008 🏛 Elsevier Science 🌐 English ⚖ 59 KB

Patterns of Care, Prognosis, and Surviva

✍ Antoine Italiano; Angela Cioffi; Paola Coco; Robert G. Maki; Patrick Schöffski; 📂 Article 📅 2011 🏛 Springer 🌐 English ⚖ 384 KB

7511 POSTER Safety and efficacy results

✍ Seddon, B.; Reichardt, P.; Ruka, W.; Kang, Y.K.; Baum, C.M.; Demetri, G.D. 📂 Article 📅 2007 🏛 Elsevier Science 🌐 English ⚖ 64 KB

Use of c-KIT/PDGFRA mutational analysis

✍ M. Debiec-Rychter; H. Dumez; I. Judson; B. Wasag; J. Verweij; M. Brown; S. Dimit 📂 Article 📅 2004 🏛 Elsevier Science 🌐 English ⚖ 309 KB